Page 13 of 15 · 360 questions tagged semaglutide.
Numbers first: SURMOUNT-1 · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
Details up front: SURPASS-2 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
For reference: SURMOUNT-OSA · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Details up front: cagrilintide · tirzepatide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…
Numbers first: STEP 8 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
The particulars: oral semaglutide · survodutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising…
Setup, so nobody has to ask: dulaglutide · liraglutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can…
Numbers first: cagrilintide · survodutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
The specifics, since they change the answer: TRIUMPH-3 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…
The specifics, since they change the answer: PIONEER-1 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret…
The case in front of me: SURPASS-2 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
I have three data points across nine months, which I hope is enough to see a trend. I suspect the usual explanation for this is wrong, or at least incomplete. I am…
For reference: PIONEER-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
The particulars: STEP 2 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
Conditions: survodutide · mazdutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can stop…
The case in front of me: SURMOUNT-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Stated plainly: SURPASS-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Concretely: SURMOUNT-OSA · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…
Conditions: survodutide · semaglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…
Setup, so nobody has to ask: SURMOUNT-4 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
Stated plainly: STEP 2 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
Stated plainly: dulaglutide · mazdutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My constraints are…
The case in front of me: PIONEER-1 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
I have the full paper rather than the abstract, and the supplementary appendix. I would like the mechanism, because I want to be able to reason about the cases nobody…